| Host: |
HEK293 cells |
| Reactivity: |
SARS-CoV-2 |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Active Recombinant-SARS-CoV-2 Spike RBD-C-His&Avi protein was developed from hek293 cells and has a target region of C-His&Avi. For use in research applications. |
| Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4 or Supplied as a 0.22 Mu m filtered solution in PBS, pH 7.4. Contact us for customized product form or formulation. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2 Spike RBD at 2 Mu g/mL (100 Mu L/well) can bind recombinant Human ACE2 with a linear range of 0.03-3.16 ng/mL. |
| Immunogen Region: |
Arg319-Phe541 |
| Immunogen: |
Recombinant SARS-CoV-2 Spike RBD Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Arg319-Phe541) of sars-cov-2 Spike RBD (Accession #YP_009724390.1) fused with a 6×His, Avi tag at the C-terminus. |
| Background | Active Recombinant SARS-CoV-2 Spike RBD Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Arg319-Phe541) of sars-cov-2 Spike RBD (Accession #YP_009724390.1) fused with a 6×His, Avi tag at the C-terminus. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
